cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Apoptosis
Rituximab/alemtuzumab induce caspase-independent apoptotic pathway in CLL cells
December 14th, 2004
Rituximab/alemtuzumab induce the caspase-independent apoptotic pathway in chronic lymphocytic leukemia cells. "The monoclonal antibodies (MoAbs) alemtuzumab (anti-CD52) and rituximab (anti-CD20) produce objective clinical responses in patients with chronic lymphocytic leukemia (CLL). However, their mechanisms of action are not fully understood. "Therefore, we investigated the mechanisms of lymphoma and CLL cell killing by two anti-CD20 antibodies (rituximab, B I) and by alemtuzumab," scientists writing in the journal Annals of Hematology report. "All antibodies induced complement-independent cell death in B-lymphoid cell...
Source: cancer weekly (2004-12-14)
|
